The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, priced at $4,764. In HearAdvisor's lab testing, it earned a SoundScore of 3.94 out of 5 (B grade), placing it in the middle tier of the prescription hearing aid category.
This device demonstrates notable strength in speech clarity during quiet listening situations, scoring well above the category average. Own-voice comfort also measured above average, suggesting users may experience less of the hollow or boomy sound that can occur with some hearing aids. However, the Vivia 9 shows weaknesses in more challenging scenarios—speech understanding in noisy environments fell below average, as did music streaming quality and feedback handling.
At this premium price point, the Vivia 9 faces stiff competition. Devices like the Oticon Intent, Phonak Sphere Infinio, and Signia Active Pro IX all achieved significantly higher scores in the same price tier. Budget-conscious consumers should note that several lower-priced alternatives delivered comparable or better sound performance in our testing, including the Jabra Enhance Pro 20 available at Costco for $1,599.99.
The Resound Vivia 9 60S microRIE may suit users who prioritize speech clarity in quieter environments and value Resound's ecosystem features like iPhone and Android streaming with hands-free capability. However, those frequently navigating noisy situations or seeking top-tier streaming audio quality may find better options among its premium-priced competitors.
